

Characterisation of prefilled syringe use in an acute care setting: costs and advantages

Noran Osman,¹ Smeet Gala,¹ Alfred Harvey,² Erik P. Erdal¹

¹BD, Franklin Lakes, NJ

²BD, Research Triangle Park, NC

Objectives

This research aims to understand the impact of drug administration using prefilled syringes (PFS) compared to conventional vials/syringes on following critical clinical and economic outcomes in acute care settings:

- Patient safety
- Supply costs/cost savings
- Time savings

Methods

A targeted literature review was conducted in PubMed and Embase databases to evaluate differences between PFS and vials/syringes using terms related to:

- Patient safety
- Cost of supplies per adverse medical event
- Medication error
- Drug waste
- Preparation/dosing time

A study was included if it evaluated acute care drugs and was published in a peer-reviewed journal between 2001 and 2018. A study was excluded if it did not take place in an acute care setting or did not evaluate PFS or vials/syringes as they related to the topics above.

Results

Eight studies were included in this review, with most studies conducted in the United States and United Kingdom. Results found that the use of PFS can lead to multifactorial benefits, such as lesser medication preparation time, lesser risk of medication errors and adverse events and reduced medication wastage when compared to regular vials/syringes usage. However, initial device cost may be higher with PFS (Fig. 1).

Discussion

PFS demonstrates several advantages, including increased patient safety decreased supply and overall costs and increased time savings, that may offset the higher initial device cost of PFS.

Patient Safety

Medication errors and the associated adverse events pose a significant clinical and economic burden. The use of PFS has been shown to reduce medication errors as compared to vials/syringes, which can improve patient safety and lead to cost savings.^{2,7} A database of anesthesia-related medication errors report ~65% of errors are associated with drug administration.¹ Preventable adverse drug events associated with injectable drugs impact 1.2 million hospitalizations per year and could raise U.S. payer costs by \$2.7–\$5.1 billion annually (*about \$600,000/hospital*).⁹

Supply Costs/Overall

Use of PFS reduces medication wastage, leading to cost savings. Preventable drug wastage from using a single-use vial can cost an institution ~\$200,000.¹⁰ PFS may lead to cost savings by reducing drug wastage caused by vials.²


Time Savings

Use of PFS may reduce drug administration time. It is imperative to administer medications without delay, especially in an acute care setting. PFS may help with timely administration in critical situations, which may help avoid complications and result in cost savings.

Conclusion

PFS demonstrated institutional cost savings compared to vials/syringes and increased patient safety. PFS prove to be effective devices for administering medications in acute care settings. PFS may have an initial higher device cost compared to vials and syringes, but these costs are easily offset in the acute care setting by reducing patient adverse event rates, medication errors, supply costs and time wastage.

Figure 1. Advantages and disadvantages associated with the use of prefilled syringes



References

1. Lobaugh LMY, et al. Medication errors in pediatric anesthesia: a report from the Wake Up Safe Quality Improvement Initiative. *Anesth Analg*. 2017;125(3):936-942.
2. Benhamou D, et al. Ready-to-use pre-filled syringes of atropine for anaesthesia care in French hospitals—a budget impact analysis. *Anaesth Crit Care Pain Med*. 2017;36(2):115-121.
3. Adapa RM, et al. Errors during the preparation of drug infusions: a randomized controlled trial. *Br J Anaesth*. 2012;109(5):729-734.
4. Stratman RC, Wall MH. Implementation of a comprehensive drug safety program in the perioperative setting. *Int Anesthesiol Clin*. 2013;51(1):13-30.
5. Pichon-Riviere A, et al. Oxytocin in Uniject disposable auto-disable injection system versus standard use for the prevention of postpartum hemorrhage in Latin America and the Caribbean: a cost-effectiveness analysis. *PLoS ONE*. 2015;10(6):e0129044. doi:10.1371/journal.pone.0129044.
6. Barber, ND; Hoffmeyer UK; Hoffmeyer, Ullrich K. Heparin administration using prefilled syringes or ampoules: a comparative cost-effectiveness study. *Int J Pharm Pract*. 1993;2(1):15-17.
7. Murdoch H, Jordan L, Tuckey J. Pre-filled thiopental syringes reduce cost and wastage whilst improving safety. *Int J Obstet Anesth*. 2012;21(4):384-385.
8. Vogl TJ, Wessling J, Buerke B. An observational study to evaluate the efficiency and safety of Ioversol pre-filled syringes compared with Ioversol bottles in contrast-enhanced examinations. *Acta Radiol*. 2012;53(8):914-920.
9. Lahue BJ, et al. National burden of preventable adverse drug events associated with inpatient injectable medications: healthcare and medical professional liability costs. *Am Health Drug Benefits*. 2012;5(7):1-10.
10. Atcheson CL, et al. Preventable drug waste among anesthesia providers: opportunities for efficiency. *J Clin Anesth*. 2016;30:24-32.

Conference: 24th Congress of the EAHP (European Association of Hospital Pharmacists) SPSQ-093

V03–All other therapeutic products

Contact information: noran.osman2@bd.com

Disclosure: All authors are BD associates

bd.com

BD and the BD Logo are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved.

